enlitenai.com

What It Is

EnlitenAI is a digital health and AI company whose core product, Neuroliten, is positioned as a decision-support software platform for the treatment of neurological and neurobehavioral disorders. According to its website, Neuroliten has been registered/listed with the U.S. FDA as a Class I Software as a Medical Device under the OUG product code. Its initial focus is seizure management, aiming to turn passive monitoring into proactive, personalized support for clinical intervention.

Core Capabilities

Neuroliten emphasizes being “device agnostic” and “data hungry,” aggregating multimodal data from wearables, implanted devices, vital signs, EEG, caregiver observations, seizure audio/video, adverse drug reactions, and more. Caregivers can record seizure severity, triggers, and event details; patients can continuously upload data via devices such as Apple Watch 6+ and Emotiv EEG; neurologists can review medical history, specific events, and monthly overview dashboards in the cloud. Its AI engine is mainly used for advanced data analysis and insight generation to support clinical management, but the website does not disclose specific models, performance metrics, or validation data.

Pricing and Compliance

The website does not disclose pricing, subscription options, trial policies, or payment methods. On privacy, the platform says audio/video and other data are stored on a highly secure cloud platform and protected with proprietary encryption technology; information sharing is driven by patient consent. The product also explicitly states that it does not provide diagnosis or treatment advice and does not replace a physician’s independent judgment, which aligns with the more cautious regulatory boundaries typically applied to clinical decision-support tools.

Pros and Cons

Its strengths lie in focusing on epilepsy, a common and complex real-world management challenge, while covering patients, caregivers, neurologists, and potential pharmaceutical or medical device partners. It is also backed by a team with experience in AI, big data, neurology, and regulation. The limitations are also clear: its AI capabilities are described in relatively conceptual terms, with little clinical effectiveness evidence; API and EHR/EMR integration methods are unclear; and use cases beyond epilepsy—such as autism, PTSD, anxiety, depression, and Parkinson’s disease—remain more of a platform vision than demonstrated applications.

Who It’s For and Access from China

This tool is better suited to epilepsy specialty management teams, neurologists, healthcare institutions running remote follow-up programs, and pharmaceutical or device partners looking to accumulate real-world data. For ordinary patients without support from a doctor or institution, its value may be limited. Information on access from China, payment, and local compliance has not been disclosed. Actual use may be constrained by cross-border medical data rules, device ecosystems, and regulatory certification. In China, hospital-based specialty follow-up systems, remote patient management platforms, and local wearable health monitoring solutions may be worth considering as alternatives.